SCHEMBL4194032

SCHEMBL4194032

CC(CC1CCCCC1)NCc1ccccc1NS(=O)(=O)c1ccc2[nH]c(N)nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 9/20 0.40
TP53 P04637 7/20 0.40
LMNA P02545 5/20 0.38
TDP1 Q9NUW8 4/20 0.38
POLB P06746 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPK1 P28482 1/20 0.34
PTGES2 Q9H7Z7 1/20 0.34
MTOR P42345 1/20 0.34
TYMS P04818 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
USP2 O75604 1/20 0.33
HSD17B10 Q99714 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190871 0.92 MAPT (0.49) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL9986701 0.86 KDM4E (0.41) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4190629 0.86 ALDH1A1 (0.41) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4192953 0.83 MAPT (0.47) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4192891 0.83 POLB (0.52) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4191257 0.83 PKM (0.45) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4200061 0.82 KDM4E (0.43) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4186036 0.82 POLB (0.52) PKMKDM4EALDH1A1MAPTTP53
SCHEMBL4184516 0.82 KDM4E (0.53) PKMKDM4EALDH1A1MAPTLMNA
SCHEMBL4188260 0.82 PKM (0.43) PKMKDM4EALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 PKM 1855/4885KDM4E 3328/4885ALDH1A1 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.